.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Cerilliant
Baxter
Moodys
Dow
Teva
Accenture
Merck
Healthtrust
Johnson and Johnson

Generated: November 17, 2017

DrugPatentWatch Database Preview

CALAN Drug Profile

« Back to Dashboard

What is the patent landscape for Calan, and what generic Calan alternatives are available?

Calan is a drug marketed by Gd Searle Llc and Pfizer and is included in three NDAs.

The generic ingredient in CALAN is verapamil hydrochloride. There are sixteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc
CALAN
verapamil hydrochloride
TABLET;ORAL018817-003Feb 23, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Pfizer
CALAN SR
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL019152-002Dec 15, 1989DISCNYesNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
CALAN
verapamil hydrochloride
TABLET;ORAL018817-004Feb 23, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Pfizer
CALAN SR
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL019152-001Dec 16, 1986ABRXYesYes► Subscribe► Subscribe► Subscribe
Gd Searle Llc
CALAN
verapamil hydrochloride
TABLET;ORAL018817-001Sep 10, 1984ABRXYesNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
CALAN
verapamil hydrochloride
TABLET;ORAL018817-002Sep 10, 1984ABRXYesYes► Subscribe► Subscribe► Subscribe
Pfizer
CALAN SR
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL019152-003Mar 6, 1991ABRXYesYes► Subscribe► Subscribe► Subscribe
Gd Searle Llc
CALAN
verapamil hydrochloride
INJECTABLE;INJECTION019038-001Mar 30, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Accenture
Colorcon
QuintilesIMS
McKinsey
Federal Trade Commission
Chinese Patent Office
Harvard Business School
Julphar
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot